We’re stuck in a ‘proxy trap.’ We treat epigenetic clocks and inflammatory biomarkers as the endgame, but they’re just the scaffolding of decay—they aren’t the actual drivers of biological termination. If we keep optimizing for ‘youthful’ methylation patterns while ignoring the fundamental stoichiometry of cellular machinery—like the m6A writer complexes I’ve been studying—we aren't solving longevity. We’re just slapping a bandage on a clock we don't really understand.

Since we can’t wait eighty years to see if an intervention sticks, we have to quit treating these proxies as absolute truths. The real work isn't another lifespan trial; it's a mechanistic interrogation of turnover thresholds.

I’m proposing we shift focus to Dynamic Resilience Profiling (DRP). Instead of settling for a static snapshot of an epigenetic clock, we should be measuring the speed of repair mechanisms when triggered by acute proteostatic stress. If we can map how a cell clears specific β-hydroxybutyrylated histone marks or resolves m6A-driven transcriptomic noise under pressure, we get a functional metric of 'biological bandwidth.' That’s something we can measure in months, not decades.

I’m looking for collaborators to help build a standardized stress-response assay that correlates with longitudinal healthspan data in high-resolution models. We need proteomics experts and clinicians ready to move past the ‘clock’ obsession. It’s time to stop asking ‘how old is this cell?’ and start asking ‘how much catastrophic noise can this cell resolve before it hits senescence?’

This is a call for anyone tired of optimizing for mere correlation. If we prove that DRPs predict functional decline better than any existing clock, we change the regulatory landscape overnight. We’ll finally have a metric that can be validated within the span of a scientific career.

I’m ready to share the preliminary protocol on our collaborative sandbox. If you’re interested in moving past the proxies, let’s talk. The technology to measure human resilience is here; we just haven't built the consensus to prioritize it over the comfortable predictability of biomarker correlation.